Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.
about
Piecing together the humoral and cellular mechanisms of immune thrombocytopeniaThe Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and PathogenesisRituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.Cellular immune dysfunction in immune thrombocytopenia (ITP).Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia.Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines.A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review.Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthy.Advances in the pathophysiology of primary immune thrombocytopenia.Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia.Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)Regulatory T cells in multiple sclerosis and myasthenia gravis.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.The interplay between bacillus Calmette-Guérin and Treg cells and its role to prevent or cure inflammatory diseases.Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis.Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia.Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.Emerging Concepts in Immune Thrombocytopenia.[Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
P2860
Q27024841-369A28CF-5023-433F-89EC-5A11485911B2Q28068881-9B428D6C-9E1C-4FD7-A734-19D264DFDDB5Q33401321-88006D58-2DB0-4A7B-A284-FE200CF7795DQ33402453-80952EC4-AB35-4ED0-B755-D266013F14DAQ33404032-910CA01F-0194-4F3C-99CB-BB25D4C326DCQ33406040-3FFEDFE4-BD9E-462B-94B1-E9089FD52179Q33406310-C0FEEAED-4D12-4C03-A9B7-216F733C6866Q33409710-6FD9FD19-29CD-441F-A89B-170938C16060Q33412264-3CF0420E-2A2F-4100-B5E8-BBB197CC05F6Q33414858-8DA61BE5-D7D8-4D4D-B1F4-7F74A92605AFQ33422782-CCC7C000-D254-4DE9-B82D-3D9AE534158EQ33426717-CE72807A-1B9A-495A-BA4E-631D365FBD7CQ33433705-895DAA72-C513-41F4-90AE-72DE891056C4Q33434310-2DD3E0B0-3216-4DF9-98DF-A46DF0670941Q33435590-385F4B57-E202-4C48-9DA4-6B64306E5FB1Q33436930-A47CFDF8-9A6C-4CEF-8A65-7724ABEE6C0BQ33439412-95C637FA-C5D7-4E8B-BD84-EF38B9DFE9ACQ33784969-8D8F7E00-8A70-4E18-9186-458F4086B7A6Q37620483-BBF74064-9F5C-4704-B0BA-80AF3C30D0DBQ38212488-62E409A8-E54D-45FD-AEAB-581D1C248209Q42694850-334ECDEB-C3F4-45A0-B564-0A31DF197374Q47876652-F2E4B493-DDB4-4E35-832E-1EE3FF1C9F76Q49293079-7270F63E-C480-40F6-9D79-3A846BCE33ACQ50872769-A0B5D5FE-5BEE-4882-9DB0-BA6E70EC9AE0Q54211951-E872F42B-79EA-4E0F-A596-D8668ADFE54BQ55431535-53EAD91B-7EB3-44D4-8EBD-CF5A2E6B9FB6
P2860
Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@ast
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@en
type
label
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@ast
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@en
prefLabel
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@ast
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@en
P2093
P2860
P1476
Low-dose rituximab combined wi ...... with immune thrombocytopenia.
@en
P2093
Weiwei Mou
Xiuying Pan
P2860
P2888
P356
10.1007/S12185-010-0753-Z
P577
2010-12-29T00:00:00Z
P6179
1031733750